Gender is a fundamental factor in one’s health and well-being. By promoting access to medicine and healthcare for women and girls, Mylan contributes to their independence, equality and welfare. Mylan has a goal to provide contraceptives to 25 million women and girls by 2020. Already, we have made progress. In 2017, we provided 11 million women and girls with contraception. Our contraceptives are currently registered in 50 of the 69 countries supported by the FP2020 initiative, some of which are among the poorest in the world. Our average price per couple-years of protection was $3.50 per year in low- and middle-income countries. Mylan has contraceptive products with active/pending registration in 95 countries globally and has submitted Medroxyprogesterone Acetate, an injectable contraceptive, for prequalification by the WHO.